

Reproduced from Panowski et al. "Site-specific antibody drug conjugates for cancer therapy"
mAbs **2014**, 6(1), 34-45.





Fig. 1

*Fig. 2*

In some embodiments, a useful scheme is depicted below:




Fig. 3

Cmp. 1101 payload standard curve




Fig. 4A

Cmp. 1101 reagent standard curve






Fig.

4B

**Fig. 4C**



Payload conc.	Peak Area
10 μ M	3721.2
5 μ M	1540.7
2 μ M	464.0
1 μ M	113.0
0.5 μ M	10.1
0.2 μ M	NA

Fig. 5





Fig. 6



μ ABT conc.	Peak Area
14 μ M	28710.7
7 μ M	13780.8
3.5 μ M	6388.4
1.75 μ M	2743.1
0.7 μ M	827.2
0.35 μ M	271.4
0.21 μ M	99.7

Fig. 7